1 / 34

Part 3 Cholinoceptor Antagonists

Part 3 Cholinoceptor Antagonists. A Muscarinic receptor antagonists. Action sites of cholinoceptor antagonist. N. M. Action sites of cholinoceptor antagonist. Atropine-like alkaloids. Atropine 阿托品. Scopolamine 东莨菪碱. Anisodamine 山莨菪碱. A Muscarinic receptor antagonists. Atropine 阿托品.

mlargent
Download Presentation

Part 3 Cholinoceptor Antagonists

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Part 3Cholinoceptor Antagonists

  2. AMuscarinic receptor antagonists

  3. Action sites of cholinoceptor antagonist

  4. N M Action sites of cholinoceptor antagonist

  5. Atropine-like alkaloids Atropine阿托品 Scopolamine东莨菪碱 Anisodamine 山莨菪碱

  6. AMuscarinic receptor antagonists Atropine 阿托品 • 1. Pharmacological effects • (1) Inhibition of exocrine gland secretion • salivary, sweat glands • tear, respiratory tract glands • relatively ineffective: GI tract • (2) Eyemydriasis • rise in intraocular pressure • paralysis of accommodation

  7. atropine pilocarpine

  8. Durations of the action atropine-like drugs on eye

  9. AMuscarinic receptor antagonists • (3) Antispamodic action on smooth muscle • sensitive: GI, urinary bladder (spasmodic state) • relatively insensitive: bile duct, urinary tract, bronchial tract • insensitive: uterus • (4) HeatHR↓: because of M1 blockade; • HR↑:if vagal tone ↑ • A-V conduction:if vagal tone ↑

  10. AMuscarinic receptor antagonists • (5) Blood vessels and blood pressure • Therapeutic doses: no remarkable effect • Larger doses:vasodilatation in the skin (indirect) • and in septic shock • (6) Central stimulation • Larger doses

  11. AMuscarinic receptor antagonists • 2. Clinical uses • (1) Spasms of smooth muscles • GI, biliary or renal colic, enuresis • (2) Inhibiting exocrine gland secretion • Preanesthetic medication, over-secretion • (3) Ophthalmology • Acute iritis or iridocyclitis: mydriatics/miotics • Measurement of the refraction: children

  12. AMuscarinic receptor antagonists • (4) Bradyarrhythmia • sinus or nodal bradycardia, A-V block • (5) Septic shock • (6) Antidote for organophosphate poisoning

  13. AMuscarinic receptor antagonists • 3. Adverse effects • (1) Side effects • (2) Central toxicity • Lethal dose: 80~130 mg (adults), 10 mg (child) • but not including the case of treating • organophosphate toxication

  14. AMuscarinic receptor antagonists • (3) Detoxication • Symptomatic treatment: diazepam, etc. • Physostigmine (毒扁豆碱) or pilocarpine (毛果芸香碱) • (4) Contraindications • glaucoma, prostatauxe, fever

  15. AMuscarinic receptor antagonists Scopolamine 东莨菪碱 • Actions and clinical uses • Peripheral effects are similar to atropine; but has stronger central effects (depression) • Pre-anesthetic medication, prevention of motion sickness, Parkinson’s disease

  16. AMuscarinic receptor antagonists Anisodamine 山莨菪碱, 654-2 • Actions and clinical uses • Primarily acts on the smooth muscles of peripheral organs; weak in CNS, glands, eye • Septic shock, spasms of smooth muscles of GI and biliary duct

  17. AMuscarinic receptor antagonists Synthetic Substitutes for atropine • Synthetic mydriatics • Homatropine 后马托品 • shorter duration (1~2 days) • Examination of eyes generally • Tropicamide托吡卡胺 （1/4 day）

  18. AMuscarinic receptor antagonists • Synthetic Antispasmadics • Airway • Ipratropine bromide 异丙托溴铵 (溴化异丙托品) • poor absorption and BBB penetration; antispasmodic effects in bronchial smooth muscle • treatment of bronchial asthma and chronic bronchitis; injection or aerosol

  19. AMuscarinic receptor antagonists • G.I. • Propantheline bromide 溴化丙胺太林 (普鲁本辛) • poor absorption (po) and BBB penetration • antispasmodic effects in GI, treatment of peptic ulcer disease • Benactyzine 贝那替秦 (胃复康) • peptic ulcer disease with anxiety, GI and urinary bladder spasms

  20. AMuscarinic receptor antagonists • M1 receptor antagonists • Pirenzepine 哌仑西平 • inhibition of gastric acid and pepsin secretion • weak in salivary glands and eye, poor penetration into CNS • used in treatment of peptic ulcer disease

  21. BNicotinic receptor antagonists

  22. BNicotinic receptor antagonists • Ganglion Blockers (NN receptor antagonists) • Acting on sympathetic and parasympathetic ganglionic cells; reducing blood pressure by inhibiting sympathetic ganglia • Short-acting; tachyphylaxis • Used for controlled hypotension

  23. BNicotinic receptor antagonists neuromuscular blockers

  24. BNicotinic receptor antagonists • 1. Depolarizing neuromuscular blockers • (depolarizing skeletal muscle relaxants) • Binding to NM receptors, initial excitation action, then persisting depolarization and resistance to ACh • initially transient fasciculations • tachyphylaxis after repeated uses • anti-AChE potentiates their effects • no ganglion-blocking effects at therapeutic doses

  25. BNicotinic receptor antagonists Succinylcholine 琥珀胆碱, Scoline

  26. BNicotinic receptor antagonists • 1.1 Pharmacological effects • Transient excitation (fasciculations), and then inhibition (relaxation) • neck, limbs > face, tongue, throat; less effective on breath muscles at therapeutic doses • Short-acting (5 min), degradation by plasma pseudocholinesterases

  27. B Nicotinic receptor antagonists • 1.2 Clinical uses • An adjuvant in anesthesia or operation • Intubation of trachea, esophagus, etc. • Prevention of trauma during electroshock therapy • Contraindicated in awake patients, should be used under anesthesia

  28. BNicotinic receptor antagonists • 1.3 Adverse effects • (1) Apnea (respiratory paralysis) • overdose or hypersensitive patients; • neostigmine potentiates the toxic effects • (2) Muscle spasm • muscular pain after operation

  29. B Nicotinic receptor antagonists • (3) Elevation of K+ in plasma • contraindicated in patients with a tendency of hyperkalemia • (4) Malignant hyperthermia • genetic abnormality • (5) Others • rise in intraocular pressure (glaucoma) • histamine release

  30. BNicotinic receptor antagonists • 1.4 Drug interactions • Thiopental • ChE inhibitors: • AChE inhibitors, cyclophosphamide, procaine, etc. • Some antibiotics: • kanamycin, polymyxins, etc. (synergism in neuromuscular blocking)

  31. BNicotinic receptor antagonists • 2. Nondepolarizing neuromuscular blockers • (nondepolarizing skeletal muscle relaxants) • 2.1 Effects: competitive blockade of NM receptors • 2.2 Uses: adjuvant treatment of anesthesia or operations Tubocurarine 筒箭毒碱

  32. B Nicotinic receptor antagonists • 2.3 Adverse effects • Respiratory paralysis:can be reversed by neostigmine • Enhancing histamine release:BP , bronchoconstriction, salivery secretion • Blocking ganglion:BP  • Contraindications:myasthenia gravis, bronchial asthma, shock, child (< 10 y)

  33. B Nicotinic receptor antagonists Other nondepolarizing neuromuscular blockers • Benzylisoquinolines （苄基异喹啉类） • atracurium 阿曲库铵doxacurium 多库铵 • mivacurium 米库铵 • Ammonio steroids（类固醇铵类） • pancuronium 泮库铵vecuronium 维库铵 • pipecuronium 哌库铵rocuronium 罗库铵

More Related